Clinical trials: Acute Decompensation of Chronic Heart Failure
Decompensated Heart Failure
Impact of Therapy Optimization on the Level of Biomarkers in Patients With Decompensated Heart Failure
In this pilot, investigator-initiated multi-centre, multinational, observational study the investigators would like to examine the impact of therapy optimization on the level of biomarkers in patients with acute decompensated and…
- Trial name
- MOLITOR (NCT01501981)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Heart Failure, Heart Decompensation
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE EARLY (NCT01064037)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 70 sites in United States, Canada and 14 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Heart Failure, Congestive
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow…
- Trial name
- NCT00357591
- Testing
- Continuous Aortic Flow Augmentation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Orqis Medical Corporation
COVID-19, Long COVID
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
We are conducting a research study at the VA hospital in Bedford, MA to learn more about how a multisensor rapid health assessment device, MouthLab, can help predict or anticipate future health complications in patients with…
- Trial name
- AIDI (NCT05713266)
- Testing
- MouthLabTM
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Edith Nourse Rogers Memorial Veterans Hospital
Chronic Heart Failure
Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation
The purpose of the study is to test the efficacy of the Functionnal ElectromyoStimulation (FES) of lower limbs in advanced chronic heart failure. The hypothesis is that FES treatment could improve functional exercise capacity.
- Trial name
- EMSICA (NCT01548508)
- Testing
- Functionnal ElectroStimulation (FES)
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 1 (NCT00525707)
- Testing
- tezosentan
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 735 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure, Acute Heart Failure
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
The main objective of the study is to determine if a diuretic adaptation protocol in the decompensation of chronic heart failure is more effective but also safer than the current non-protocolized practice.
- Conditions
- Heart Failure, Acute Heart Failure, Chronic Heart Failure
- Trial name
- ProDUCT-HF (NCT03892148)
- Testing
- Furosemide, Hydrochlorothiazide
- Where
- 9 sites in France
- Volunteers
- 299 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Heart Failure
Acute Heart Failure Monitoring Via Inferior Vena Cava Ultrasound
Known before diagnosed heart failure and used diuretic therapy patients will be admitted in this study.The objective of this work is whether the Inferior Vena Cava Ultrasound can be used for management of Acute Heart failure…
- Trial name
- NCT02725151
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Haseki Training and Research Hospital
Congestive Heart Failure
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of renal function in acute decompensation of chronic heart failure (ADHF) compared to standard therapy will be analyzed.
- Trial name
- NCT04778787
- Testing
- Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
- Where
- 2 sites in Russia
- Volunteers
- 370 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University